Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Bin Xiao"'
Autor:
Ming Li, Bin Xiao, Wenbo Hao, Haijian He, Chen Yu, Shuhong Luo, Huiqin Chen, Daxiang Chen, Daoyuan Gong, Zhenzhan Kuang, Ying-Song Wu, Yufeng Xiong, Daniel L. Rock, Mingjian Long, Fang Liu, Yong Wang
Publikováno v:
Oncotarget
Orf virus has been utilized as a safe and efficient viral vector against not only diverse infectious diseases, but also against tumors. However, the nature of the genes triggered by the vector in human cells is poorly characterized. Using RNA sequenc
Autor:
Youping Liu, Jinju Wang, Ying Cheng, Run Chen, Chunyan Duan, Chunhong Feng, Rongyang Dai, Bin Xiao, Hong Li, Fuli Yao, Hong Zhou, Jing Li, Chunyan Zhang, Xiaofang Zhao
Publikováno v:
Oncotarget
// Xiaofang Zhao 1, * , Chunyan Zhang 1, * , Hong Zhou 1, * , Bin Xiao 1 , Ying Cheng 1 , Jinju Wang 2 , Fuli Yao 1 , Chunyan Duan 1 , Run Chen 3 , Youping Liu 2 , Chunhong Feng 2 , Hong Li 1 , Jing Li 2 , Rongyang Dai 1 1 Department of Biochemistry
Autor:
Shuwen Liu, Juan Li, Bin Xiao, Wei Zhang, Lijie Song, Chuanhong Yang, Jie Wang, Linhai Li, Xiaomei Kou, Li Wang, Yan Wang
Publikováno v:
Cancer Science
The underlying mechanisms of breast cancer cells metastasizing to distant sites are complex and multifactorial. Bone sialoprotein (BSP) and αvβ3 integrin were reported to promote the metastatic progress of breast cancer cells, particularly metastas
Autor:
Ze‑Zhou Feng, Zhao Jian, Peng Liu, Ying‑Bin Xiao, Wei‑Kun Jia, Yun Zhu, Liang Zhao, Jingwei Li, Si‑Yi He
Publikováno v:
Molecular Medicine Reports. 12:6903-6910
MicroRNAs (miRs) regulate a number of physiological and pathological processes, including myocardial chronic hypoxia. Previous studies revealed that the expression of miR-146b is increased in vitro and in vivo following the induction of hypoxia. In t
Autor:
Fuli Yao, Jing Li, Xiaofang Zhao, Yong Wang, Ying Cheng, Chunyan Duan, Chunhong Feng, Xianming Xia, Rongyang Dai, Guosong Luo, Wenjing Yu, Mei Wei, Hong Zhou, Bin Xiao
Publikováno v:
Molecular medicine reports. 18(2)
Although activating transcription factor 4 (ATF4) is involved in the regulation of numerous biological functions, whether ATF4 has a direct role in liver injury is unknown. The aim of the present study was to investigate the role of ATF4 in liver inj
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 10, p e0164105 (2016)
PLoS ONE, Vol 11, Iss 10, p e0164105 (2016)
Increasing evidence has indicated that many microRNAs participate in the development and progression of esophageal cancer and gene expression regulation. MicroRNA-20b (miR-20b) has been reported to be aberrantly expressed in various cancers, but its
Publikováno v:
Chinese Journal of Cancer. 29:741-746
BACKGROUND AND OBJECTIVE Rosiglitazone is a peroxisome proliferators-activated receptor gamma (PPARgamma) ligand, which inhibits tumor growth by activating PPARgamma signaling pathways. Fluorouracil (5-FU) is one of the commonly used chemotherapeutic
Autor:
Cheng Luo, Xi-Long Ou, Guo-Xian Ding, Yuan Zhang, Qin-Shi Zhao, Ye Yang, Guo-Sheng Chen, Yi-Ping Xue, Yun Shao, Wei-Hao Sun, Hai-Chen Xu, Bin Xiao, Su-Ming Zhou
Publikováno v:
Cancer Letters. 275:247-255
Although inhibition of cyclooxygenase-2 (COX-2) or activation of peroxisome proliferators-activated receptor gamma (PPAR-gamma) leads to growth inhibition in malignancies, the synergistic anti-tumor effects of combination of COX-2 inhibitor (NS-398)
Autor:
Christina L. Addison, James Villeneuve, Khalid N. Al-Zahrani, Grant A. Howe, Mohamed Shaad Hasim, Bin Xiao, Luc A. Sabourin, Glenwood D. Goss, Huijun Zhao, Harmanjatinder S. Sekhon, Jim Dimitroulakos
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 3, p e0150567 (2016)
PLoS ONE, Vol 11, Iss 3, p e0150567 (2016)
Blockade of epidermal growth factor receptor (EGFR) activity has been a primary therapeutic target for non-small cell lung cancers (NSCLC). As patients with wild-type EGFR have demonstrated only modest benefit from EGFR tyrosine kinase inhibitors (TK
Publikováno v:
Cancer Research. 74:753-753
The epidermal growth factor receptor (EGFR) is over-expressed in approximately 90% of non-small cell lung cancer (NSCLC) and as such, blockade of EGFR activity has been a primary therapeutic target for NSCLC. As patients with wild-type EGFR have demo